Assessing Treatment Options for ALK+ NSCLC
This video segment provides an in-depth discussion on the first-line use of lorlatinib for ALK-positive metastatic NSCLC, including clinical evidence from the phase 3 CROWN trial, the broader therapeutic landscape and alternative strategies, real-world insights on lorlatinib's performance, and key considerations for selecting among ALK inhibitors based on patient-specific factors.
Video content above is prompted by the following:
- Can you summarize the clinical evidence supporting lorlatinib use in the first-line treatment of ALK+ metastatic NSCLC?
- Could you highlight the primary efficacy outcomes from the phase 3 CROWN trial?
- How would you describe the current therapeutic landscape metastatic ALK+ NSCLC?
- What alternative treatment strategies could have been considered for this patient?
- Based on your clinical experience, how has lorlatinib performed in real-world practice?
- What advantages and challenges have you encountered when incorporating lorlatinib into your treatment protocols?
- How do you approach the selection process among the various available ALK inhibitors?
- What key factors influence your decision?
- In which specific patient subgroups would you lean towards using alectinib, lorlatinib, or brigatinib (the NCCN preferred treatments)?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
